SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-24-000419
Filing Date
2024-01-03
Accepted
2024-01-03 16:45:23
Documents
2
Period of Report
2024-01-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 8601
2 POA DOCUMENT poa.txt EX-24 3034
  Complete submission text file 0001209191-24-000419.txt   13151
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Issuer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130
Business Address
DiRaimondo Thomas (Reporting) CIK: 0002005618 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40475 | Film No.: 24507475